RxDoctor Payments Data

Douglas Laidlaw, MD

Clinical Cardiac Electrophysiology · Worcester, MANPI 1124167911

Payments from drug & device makers

$6,254in general payments, 2019–2025

Across 265 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Pfizer$949
  • E.r. Squibb & Sons, L.L.C.$688
  • Novartis$632
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$564
  • Boehringer Ingelheim$431
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$431%
  • Travel & lodging$72012%
  • Food & beverage$5,49188%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,254 in reported general payments places this provider in the 30th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$125,226
Medicare patients
636
Services billed
1,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban296$314,164
XareltoRivaroxaban30$43,911
EntrestoSacubitril/Valsartan21$36,395
Flecainide Acetate150$8,103
Metoprolol Succinate218$5,067
Mexiletine Hcl11$1,247
Amiodarone Hcl57$1,173
Diltiazem 24hr Er (Cd)Diltiazem Hcl18$956
Dilt-XrDiltiazem Hcl23$889
Atenolol28$644
Spironolactone54$614
Metoprolol Tartrate48$439
Losartan Potassium22$338
Atorvastatin Calcium25$315
Furosemide29$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$949$314,164296 claims
Johnson & JohnsonXarelto$362$43,91130 claims
NovartisEntresto$632$36,39521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →